ArticleVox sanguinis2025
Characterization of the in vitro quality parameters of cold-stored platelets containing aggregates.
Article in Vox sanguinis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Factors associated with aggregate formation in cold-stored platelets.Vox sanguinis · 2026Article
- Characterization of the in vitro quality parameters of cold-stored platelets containing aggregates.Vox sanguinis · 2025Article
- Cold-stored platelets: revisiting assumptions and addressing variability to support implementation.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND AND
objectivesCold-stored platelets (CSP) are being used more widely for the treatment of bleeding because of their longer shelf life. However, storage at low temperatures can induce the formation of platelet aggregates. We aimed to study the impact of aggregate formation on platelet quality and function. MATERIALS AND
methodsApheresis platelets (40% plasma/60% platelet additive solution [PAS-E]) were refrigerated (2-6°C) for 21 days. CSP that developed aggregates (n = 44) were compared with CSP with no aggregates (controls; n = 45). A subset of aggregated CSP (n = 15) was tested before and after being passed through a transfusion administration set containing a 200-μm filter. Donor- and collection-related parameters and in vitro quality parameters were assessed.
resultsAggregates were identified in 10.9% of CSP, primarily being found following extended storage (median: 16 days). The platelet count was not different between the aggregated (928 ± 158 × 10
conclusionPlatelets within components that contained aggregates were more activated than non-aggregated controls. The propensity for aggregate formation should be considered when selecting a shelf life for CSP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.